All Julian Marchesi articles

News

EnteroBiotix announces completion of enrolment in Phase 2a Trial evaluating EBX-102-02 prior to allogeneic stem cell transplantation

2026-03-10T12:44:00Z

EnteroBiotix announced that the investigator-initiated Phase 2a MAST trial has completed its enrolment of 50 adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) for defined haematological malignancies.